REDUCED ANTIGENIC CELLS AND USES THEREFOR

Abstract: The present invention provides a composition of matter, comprising a red blood cell coated with a polymeric mixture of polyethylene glycol and albumin. Also provided is a method of blocking blood group antigens on the surface of a red blood cell, comprising the step of contacting said cell with a pharmacologically effective concentration of the composition of the present invention.

Description: REDUCED ANTIGENIC CELLS AND USES THEREFOR BACKGROUND OF THE INVENTION Cross-reference to Related Application This non-provisional patent application claims benefit of provisional patent application U.S. Serial number 60/060, 235 , filed September 26, 1997, now abandoned. Field of the Invention The present invention relates generally to the fields of molecular biology and erythrocyte biochemistry. More specifically, the present invention relates to reduced antigenic cells and uses therefor. Description of the Related Art Many polymorphic blood group antigens are expressed on the surface of human red blood cells (Issitt 1985; Mollison, Engelfriet, and Contreras 1987). These include the well-known ABO type and Rh antigen (also termed D antigen) as well as many other less familiar antigens. As a consequence of the antigenic diversity of red cells, it is not possible to transfuse blood that is antigenically identical with a recipient, unless blood is provided by autologous donation or by an identical twin. Recipients of multiple transfusions develop antibodies against the nonself antigens on red cells. Alloimmunization also can occur during pregnancy if there is fetal-maternal exchange of blood. As antibodies to other individuals' red cell antigens develop, it becomes progressively harder to provide compatible blood and to avoid transfusion reactions. Transfusion of compatible blood also becomes impossible in patients with autoimmune disorders who produce antibodies against antigens of their own red blood cells. The r e d cells in individuals with autoimmune disorders and any transfused red cells are destroyed, producing an autoimmune hemolytic anemia which can be fatal in severe cases. The prior art is deficient in the lack of effective me ans of producing red cells that are compatible with all recipients an d reduced antigenic cells and uses therefor. The present invention fulfills this longstanding need and desire in the art. SUMMARY OF THE INVENTION Cell antigens, such as red cell antigens can be masked with a nonantigenic polymer, polyethylene glycol (PEG), as a means of producing red cells are compatible with all recipients, including those with multiple alloantibodies or autoantibodies to red cells. In previous studies, the technique of covalent coupling polyethylene glycol (PEG) derivatives to the surface of red cells a s a means of covering blood group antigens and producing cells th at could serve as universal donor cells for transfusion was described . Effective blockade of red cell antigens was achieved with activated esters of polyethylene glycol. The present invention involves a second generation technique which is an improved procedure in which multiple layers of polyethylene glycol-albumin copolymers are generated instead of single layer of individual polyethylene glycol polym er on red cell surface. This new technique showed less red cell damage and was much more efficient in blocking red cell antigen- antibody reactions. The mouse red cell survival studies showed normal 27 days red cell life span similar to untreated mouse r e d cells. This new technique offer potential for universal donor re d cells for blood transfusion. In one embodiment of the present invention, there i s provided a composition of matter, comprising a red blood cell coated a polymeric mixture of polyethylene glycol and albumin. In yet another embodiment of the present invention, there is provided a method of blocking blood group antigens o n the surface of a red blood cell, comprising the step of contacting said cell with a pharmacologically effective concentration of th e composition of the present invention. In yet another embodiment of the present invention, there is provided a composition of matter, comprising a cell coated with a cross-linked or branched polyethylene glycol and a protein. Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of th e invention given for the purpose of disclosure. BRIEF DESCRIPTION OF THE DRAWINGS So that the matter in which the above-recited features , advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is noted, however, that th e appended drawings illustrate preferred embodiments of th e invention and therefore are not considered limiting in their scope. Figure 1 shows the polyethylene glycol-albumin polymers treated mice red blood cells have the same survival over 27 days. Figure 2 shows the polyethylene glycol treated mouse red blood cells only had a 3 day life span. In contrast, untreated red blood cells had a 27 day life span. Figure 3 shows the red cell survival over 27 days in mice red blood cells treated with the polyethylene glycol-albumin polymers after the red cells were treated in AS-5 additive solution for 7 days. Figure 3 shows the 40% of control untreated mice r e d blood cells and 60% of the red cell was rapidly cleared within one day. These represent a fraction of damaged red cells after one week storage in AS-5 additive solution that was rapidly cleared. AS-5 additive solution is designed to preserve human red blood cells and may not be optimal for mice red blood cells. The remaining red blood cells after one day transfusion showed similar survival curve when compared to untreated red blood cells. Figure 4 shows the data shown in Figure 3 except survival is shown as a percentage of cells present at one d ay transfusion ( ld=100%). Figure 5 shows the red cell morphology after polyethylene glycol-albumin copolymers treatment of human re d blood cells in a wet preparation in normal saline (x700). The bottom panel shows control untreated human red blood cells DETAILED DESCRIPTION OF THE INVENTION In the present invention, coupling of an inert polymer to the surface of red cells was examined as a means of covering blood group antigens and producing cells that could serve a s universal donor cells for transfusion. Effective blockade of r e d blood cell antigens was achieved with N-hydroxysuccinimide- activated esters of polyethylene glycol. It was possible to block all antigens tested, but lower concentrations of reactants w ere required to block peptide-defined antigens than c arbohydrate- defined antigens. Red cells remained intact after modification b u t were significantly damaged. The present invention demonstrates the feasibility of antigenic blockade of red cells and that damage can be reduced during coupling reactions to produce viable re d cells. The present invention is directed to a composition of matter, comprising a red blood cell coated with an inert, nonantigenic polymer. Preferably, the polymer is a N- hydroxysuccinimide-activated esters of polyethylene glycol. The polymer may be a bis(propionyl-N-hydroxysuccinimide)- polyethylene glycol. Alternatively, the polymer is propionyl-N- hydroxysuccinimide-methoxypolyethylene glycol with a molecular weight of 5,000. Preferably, the red blood cell coated with a n inert, nonantigenic polymer has been treated with a concentration of from about 1 % of the polymer. The present invention is also directed to a method of blocking blood group antigens on the surface of a red blood cell, comprising the step of contacting said cell with a pharmacologically effective concentration of the composition of the present invention. Preferably, the blocking of the blood group antigens on the surface of the cell significantly reduces th e antigenicity of such red blood cells when administered to a n individual in need of such treatment. Preferably, the polymer is a N-hydroxysuccinimide-activated esters of polyethylene glycol. The polymer may be a bis(propionyl-N-hydroxysuccinimide)- polyethylene glycol. Alternatively, the polymer is propionyl-N- hydroxysuccinimide-methoxypolyethylene glycol with a molecular weight of 5,000. Preferably, the red blood cell coated with a n inert, nonantigenic polymer has been treated with a concentration of about 1 % of the polymer. Many polymorphic blood group antigens are expressed on the surface of human red blood cells (Issitt 1985 ; Mollison, Engelfriet, and Contreras 1987). These include the well-known ABO type and Rh antigen (also termed D antigen) as well as m an y other less familiar antigens. As a consequence of the antigenic diversity of red cells, it is not possible to transfuse blood that is antigenically identical with a recipient, unless blood is provi ded by autologous donation or by an identical twin. Recipients of multiple transfusions develop antibodies against the nonself antigens on red cells. Alloimmunization also can occur during pregnancy if there is fetal-maternal exchange of blood. As antibodies to other individuals' red cell antigens develop i t becomes progressively harder to provide compatible blood and to avoid transfusion reactions. Transfusion of compatible blood also becomes impossible in patients with autoimmune disorders wh o produce antibodies against antigens of their own red blood cells. Their own red cells and any transfused red cells are destroyed, producing an autoimmune hemolytic anemia which can be fatal i n severe cases. It is also important to note that not all antigens need to be blocked on each cell for the present compositions to have utility. For example, one may only block Rh determinant o n cells which could be useful for autoimmune hemolytic problems. The masking of red cell antigens with a nonantigenic polymer, polyethylene glycol (PEG), as a means of producing r e d cells compatible with all recipients, including those with multiple alloantibodies or autoantibodies to red cells is shown herein. The first generation technique which conjugated polyethylene glycol polymer to the red cell surface to decrease red cell agglutination showed only partial blockage of red cell antigen-antibody reaction and moderate damage of red cell membrane. Significant reduction in red cell damage resulted from use of a group of polyethylene glycol reagents that were of higher molecular weight. However, blockade of antigens were still incomplete. The present invention shows the development of a second generation improved technique which conjugates a small amount of polyethylene glycol-albumin copolymers on the red cell surface first with subsequent deposition of layer by layer polyethylene glycol-albumin copolymers on top of the existing polymers on red cell surface. This new technique showed that all of the red cell antibodies could be completely blocked, except ABO antibodies which showed very weak microscopic reactions . Developing layers of cross-linked PEG-albumin copolymers to cover the red cell surface is much thicker and much more efficient in covering the red cell antigens then polyethylene glycol polymer alone. Also, these new polyethylene glycol-albumin copolymers have less attached points on red cell surface, therefore causing less damage to the red cells. This technique can be used to create universal donor red cells for blood transfusion, since it showed efficient ' blockage of red cell antigen-antibody reaction while preserving normal red cell morphology and red cell survival. Thus, the present invention relates to a composition of matter, comprising a red blood cell coated a polymeric mixture of polyethylene glycol and albumin. Generally, any protein or compound containing multiple reaction sites with activated esters which form a cross-linked matrix can be used to create th e universal donor blood cells of the present invention . Preferably, the concentration of the polyethylene glycol is from about 0.5% to about 1.0%. In addition, the preferable concentration of th e albumin is from about 1.25% to about 2.5%. Representative examples of suitable albumin formulations include Albumarc™ 5% from the American Red Cross Blood Services and Albutein® 5% from the Alpha Therapeutic Corporation. Preferably, the cell is coated with the polymeric mixture during one single reaction although multiple treatments could be applied. The present invention relates to a method of blocking blood group antigens on the surface of a red blood cell, comprising the step of contacting said cell with a pharmacologically effective concentration of the composition disclosed herein. Preferably, the concentration of the polyethylene glycol is from about 0.5% to about 1.0%. In addition, the preferable concentration of th e albumin is from about 1.25% to about 2.5%. Representative examples of suitable albumin formulations include Albumarc™ 5% from the American Red Cross Blood Services and Albutein® 5% from the Alpha Therapeutic Corporation. Preferably, the cell is coated with a polymeric mixture one time so as to allow th e interactive polyethylene glycol and albumin copolymer to develop thicker and thicker polymers on the red cell surface. This procedure can be repeated if necessary. The following examples are given for the purpose of illustrating various embodiments of the invention and are no t meant to limit the present invention in any fashion. EXAMPLE 1 Materials and methods Polyethylene glycol (PEG) derivatives were purchased from Shearwater Polymers (Huntsville, AL). Red blood cells w ere obtained from segments attached to units of donor red blood cells. Imucor (Norcross, GA) was the source of monoclonal/polyclonal anti-human globulin, antibodies to human red cell antigens. Fresh porcine blood was obtained from the Animal Care Facility. Lectins were purchased from Gamma Biologicals (Houston, TX). Red blood cell bound antibody was measured by the UAB Immunecytopenia Laboratory using an immunoassay as previously described b y LoBuglio et al ( 1983). Agglutination reactions of red cells w ere assayed by standard tube techniques as described by th e Technical Manual for blood banks (Walker et al., 1990) . Quantitative estimates of the strength of agglutination reactions after serial dilution of the agglutinating serum. Strength of agglutination is expressed as a titer scores which relates to th e inverse of the dilution yielding agglutination. Coupling of activated polyethylene glycols to red blood cells was conducted in 140 mM NaCl, 20 mM N- [2- hydroxyethyl)piperazine-N'[2-ethanesulfonic acid] (HEPES) adjusted to pH 8.0. A 5% suspension of red blood cells was mixed at 4°C with activated polyethylene glycol derivatives added to varying percentages by weight. Incubations were at 4°C overnight. Cells were washed in a centrifugal cell washer before any analysis. EXAMPLE 2 Results Incubation of red cells overnight with the bifunctional activated polyethylene glycol derivative, bis(propionyl-N- hydroxysuccinimide)-polyethylene glycol of 3,400 daltons progressively blocked agglutination reactions by antibodies to blood group antigens such as A, A'B, and D antigens as th e concentration of reagent was increased (TABLE I). The D antigen, which is one of the polypeptide-defined determinants of the Rh system, was blocked at a lower concentration than required for antigenic determinants defined by carbohydrate groups, e.g., th e very high concentration of reagent required to block the A a n d A'B antigens. It was difficult to achieve 100% blockade of agglutination against these high abundance, carbohydrate-defined blood group antigens. Preferential blockade of polypeptide- defined antigens is not surprising considering the preferential reactivity of the active carboxy esters with amino rather th an hydroxyl groups (Zalipsky and Lee 1992). Polypeptides may b e preferred sites of covalent coupling of the activated polyethylene glycols on the surface of red cells. TABLE I Blockade of blood group antigens by coupling with bis(propionyl- N- hydroxysuccinimideVpolyethylene glycol of 3,400 daltons Titer Scores for Agglutination of Red Cells ' % PEG And-A Anti A'B Anti-D 0 2048 1 024 25 6 1 0 2048 1 024 0 2 0 1024 512 0 3 0 3 2 64 0 4 0 1 6 1 6 0 5 0 2 4 0 Agglutination reactions of polyethylene glycol-modified r e d cells bearing the A, A'B, and D antigens with serial dilutions of antisera versus the respective antigens were examined. EXAMPLE 3 It was expected that use of a reagent with a large molecular size would prevent entry of the reagent into cells a n d would minimize modification or damage to internal components of cells. There was a limited amount of hemolysis of cells, and th ere was little change in the size distribution of red cells when analyzed with an electronic hematology analyzer. However, cells did undergo some damage as evident by more irregular shapes microscopically (not shown). Also, breakdown of the red cell membrane as a permeability barrier was suggested by lack of lysis of modified red cells by hypotonic solutions. Agglutination reactions are an imperfect means of assessing antigenic blockade as agglutination reactions may b e influenced by factors such as changes in surface charge of red cells or shape of cells. For this reason, an independent means of measuring the blockade of a red cell antigen was employed. Red cells expressing the D antigen were modified by coupling with th e bifunctioήal polyethylene glycol derivative. Modified cells a n d control cells were then incubated with antibody to the D antigen, and the amount of cell-bound antibody was measured b y immunoassay. This analysis shown in TABLE II indicated a complete blockade (more than 99%) of antibody binding to the D antigen. TABLE II Blockade of D antigen by coupling of bis(propionyl-N- hydroxysuccinimide)-polyethylene glycol to red cells. Red Cell Tvpe Molecules lgG/Cell A, Rh Negative 3 96 (negative control) A, Rh Positive 1 1 , 233 (positive control) A, Rh Positive, 407 polyethylene glycol-modified Cells were incubated with antibody to D antigen and antibody molecules bound measured by immunoassay. Rh negative cells lack D antigen and serve as a negative control. EXAMPLE 4 Blockade of a variety of other antigens by attachmen t of polyethylene glycol to red cells was examined (TABLE III) . Agglutination by antibodies to antigens of the Duffy (Fy), Kidd (Jk), Lewis (Le), and Rh groups (D) were inhibited as well a s agglutination reactions by the lectins from Dolichos bylorous an d Ulex europaens. These results indicate a generalized blockade of red cell antigens. The antigens most resistant to blockade by r e d cell modifications with polyethylene glycol have been the A and B antigens, which probably reflects their high abundance, peripheral location, and carbohydrate nature (Walker, 1990). TABLE III Blockade of red cell antigens by coupling of bis(propionyl-N- hydroxysuccinimide)-polyethylene glycol Agglutination Reaction Anfibody/ Lectin Untreated Cells PEG-Red cells Type Aι , Rh+ cells treated with 5 % PEG derivative Anti-D 4+ 0 Anti-Fy b 1+ 0 Anti-Jk a 2+ weak + Anti-Le b 2+ 0 Dolichos biflorous 4+ 0 Ulex europaeus 4+ 0 Type Ai B cells treated with 25 % PEG derivative Anti-B 4+ 1 + Anti~Jkb 1+ 0 Anti~Leb 3+ 0 EXAMPLE 5 Human serum has naturally-occurring antibodies to red cells of many species, such that xenotransfusion of red cells results in rapid agglutination or lysis of the cells by complement fixation. Blockade of porcine red cells by coupling of a polyethylene glycol derivative was examined as compatibility with human serum. Both agglutination and hemolytic actions of human serum were blocked by the modification of porcine r e d cells with polyethylene glycol. TABLE IV Blockade of porcine red cell antigens by propionyl-N- hydroxysuccinimide-methoxypolyethylene glycol (MW: 5.000) % PEG Agglutination Hemolysis 0 4+ Moderate 5% 3+ Slight 10% 0 None 20% 0 None 30% 0 None 40% 0 None 50% 0 None Modified porcine red cells were mixed with human serum and agglutination and lysis reactions were assessed. EXAMPLE 6 Polyethylene glycol derivatives were purchased from Shearwater Polymers (Huntsville, AL). The 5% human albumin was purchased from American Red Cross Blood Services. Red cells were obtained from segments attached to units of donor red cells. Immucor (Norcross, GA) was the source of monoclonal/polyclonal anti-human globulin, antibodies to human red cell antigens . Agglutination reactions of red cells were assayed by standard tu b e techniques as described by the Technical Manual of for Blood Banks (Walker et al 1994). Coupling of activated polyethylene glycols to red cells was conducted in 140 mM NaCl, 20 mM N- [2- hydroxyethyl)piperazine-N' [2-ethanesulfonic acid] (Hepes solution) adjusted to pH 9.0. Activated refers to polyethylene glycol which has chemically reactive esters attached. A 5% hum an albumin was mixed at room temperature with activated branched polyethylene glycol derivatives such as 4 arm branched succinimidyl derivative of PEG propionic acid (SPA-PEG) or specific product thereof- 4 arm propionyl-N-hydroxysuccinimide- methoxypolyethylene glycol MW 10,000) for one minute and th en mixed with 5% suspension of red cells for 20 minutes and th en fresh Hepes solution was added for developing polyethylene glycol-albumin copolymer layers for another 25 minutes. Cells were washed with PBS, pH 7.0 in a centrifugal cell washer before any analysis. The red cell survival studies using PKH-2 fluorescent dye technique as described by Read et al. in Transfusion Journal 31 (6): 502-508, 1991. EXAMPLE 7 Hemagglutination tests TABLE V shows that polyethylene glycol-albumin copolymers completely blocked all red cell antigen-antibody reactions except very weak microscopic agglutination with anti-A, anti-B and anti-A'B antibodies. Testing with polyclonal allo- antibodies such as anti-K, anti-FyA, anti-FyB, anti-JkA, anti-JkB , anti-S, anti-s and other Rh antibodies, showed same results a s above which indicated a complete block of antigen-antibody reaction. Testing with anti-B and anti-A'B showed same result a s above, negative on IS and 30'RT but micro + on anti-IgG phase. TABLE V Testing with polyclonal anti-D: is 15 '37C ! anti-IgG A+ untreated (control) 4+ A+ PEG-Albumin treated 0 0 0 A- untreated (control) 0 0 0 A- PEG-Albumin treated 0 0 0 Testing with human polyclonal anti-A: 30'37°C IS 30'RTanti-IgG Titer at RT A- untreated (control) 4+ 4+ 4+ 128 A-PEG-Album. treated 0 0 micro + Testing with monoclonal anti-A: IS 30'RT A- untreated (control) 4+ 4+ A- PEG-Albumin treated 0 micro + EXAMPLE 7 Red cell survival studies The red cell survival studies showed polyethylene glycol-albumin treated mouse red blood cells have the same 2 7 days life span compared with untreated red blood cells (Figure 1 ) . In contrast, polyethylene glycol treated mouse red blood cells only have 3 days life span (Figure 2). Polyethylene glycol-albumin treated mouse red blood cells (in AS-5 additive solution, a solution containing dextrose, mannitol, adenine and sodium chloride that is use to preserve human red blood cells so that such cells can b e stored for long periods of time) was stored in 4°C refrigerator for one week. When transfused back into mouse, there was a loss of 60% of transfused red blood cells in first day and the remaining red cells had a 24 day life span. The untreated control mouse re d cells showed loss of 40% of transfused red blood cells in first d ay and the remaining red cells have 27 days life span (Figures 3 and 4). The AS-5 additive was not the optimal additive solution for mouse red cells, as it showed immediate large red cell destruction on both treated and untreated mouse red cells and a slight decrease of remaining red cell survival on polyethylene glycol- albumin treated compare with untreated mouse red cells. EXAMPLE 8 Morphology of red blood cells Figure 5 shows that both polyethylene glycol-albumin treated and untreated control human red blood cells showed normal red cell morphology in microscopic examination. The present invention showed that polyethylene glycol-albumin polymers are more efficient than polyethylene glycol polymer i n covering the antigen sites on red cell surface to prevent antibodies reaction. Polyethylene glycol polymer is a single layer coated on the red cell surface, with space between each polymer which allow allows the antibody to reach the antigens. In contrast, th e polyethylene glycol-albumin copolymers are multiple layers a n d have sheet-like structures due to cross-linked or branched polyethylene glycol and albumin polymers. These sheet-like structures prevent the antibody from reaching the antigens wi th the exception of ABO antibodies as ABO antigens are far extended out from' the surface. The polyethylene glycol-albumin copolymer had more efficient coverage on red cell surface and have less attached points on red cell surface which showed normal red cell morphology and red cell survival studies indicating very minimal damage to the red cell surface. The polyethylene glycol-albumin copolymers exhibit high potential as universal donor red cells for blood transfusion. Thus, the present invention provides a composition of matter, comprising a red blood cell coated with a cross-linked o r branched polyethylene glycol and albumin. Generally, an y branched polyethylene glycol should be useful in creating th e present compositions. Preferably, "arm" polyethylene glycols which has multiple molecules connnected together with multiple actives sites are preferred. For example, 4 arm refers to 1 PEG of a MW of about 3400-5000; 4 arm refers to 4 PEG molecules of about 15,000-20000 MW. Four PEGs connected together would have therefore 4 active sites. Generally, the concentration of the polyethylene glycol is from about 0.5% to about 1% and the concentration of th e albumin is from about 1.25% to about 10%. In a preferred form, the albumin is human albumin. In another aspect, the pre sent invention can provide a white blood cell coated with cross-linked mixture of branched polyethylene glycol and albumin so as to block the antigen sites on such a cell. For all of the compositions described herein, albumin may be preferred but other similar proteins could easily be used, e.g., fibrinogen. Generally, in making the compositions described herein, the polyethylene glycol is mixed with the albumin to form a copolymer. Subsequently, the cells such as red blood cells are added. Over a short period of time, such as 20 minutes, th e copolymer attaches to the red blood cell blocking the antigen sites. The cell is coated with polymeric mixture at least one time. The present invention also provides a method of blocking blood group antigens on the surface of a red blood cell, comprising the step of contacting said cell with a pharmacologically effective concentration of the composition described herein. The present invention is also directed to a composition of matter, comprising a red blood cell coated with a cross-linked or branched polyethylene glycol and branched polyethylene glycol amine. The present invention is also directed to a composition of matter, comprising a red blood cell coated with a cross-linked or branched polyethylene glycol and an albuminlike compound, wherein said compound contains multiple reaction sites which form a cross-linked matrix with activated esters of polyethylene glycol. The present invention is further directed to a composition of matter, comprising a cell coated with a cross-linked or branched polyethylene glycol and a protein. Preferably, th e cell is a red or white blood cell but could be any cell type. In one embodiment, the protein is albumin but could be any protein contains multiple reaction sites which form a cross-linked m atrix with of polyethylene glycol. In a preferred embodiment, th e polyethylene glycol is a branched polyethylene glycol. EXAMPLE 9 Different kinds of branched amino-PEG (4 a r m branched amino-PEG m.w. 10,000 and 2 arm branched amino-PEG m.w. 3,4'00 obtained from Shearwater) were also used to replace albumin. This data supports that any protein or compound containing multiple reaction sites with activated esters which form a cross-linked matrix - equivalent substitutes for albumin can b e used to create the universal donor blood cells of the pre s ent invention. Table I showed no differences using albumin or amino- PEG to conjugate with PEG to red blood cells to block antigen- antibody reactions. TABLE VI Testing with Monoclonal anti-D: IS 15 ' 37°C anti-IgG A+ untreated (control) 4+ 4+ 4+ A-PEG-Albumin treated 0 0 0 A+ PEG-2 branched amino-PEG treated 0 0 0 A+ PEG-4 branched amino-PEG treated 0 0 0 A- untreated (control) 0 0 0 Testing with polyclonal allo-antibodies (anti-FyA, anti-FyB, anti - JkA, anti-JkB, anti-K, anti-S, anti-s) showed the same results a s above, indicating a complete block of antigen-antibody reaction TABLE VII Testing with human polyclonal anti-A: 30'37°C Titer at IS 30'RT anti-IgG RT A-untreated (control) 4+ 4+ 4+ 1 28 A-PEG-A ' lbumin treated 0 0 0 (micro +) A+ PEG-2 branched 0 0 (micro +) amino-PEG treated A+ PEG-4 branched 0 0 0 (micro +) amino-PEG treated Testing with anti-B and anti-A'B showed the same results a s above, negative on IS and 30'RT, but microscopic + on anti-IgG phase . In another study, human lymphocytes were treated with PEG-albumin copolymer as the same method used for re d blood cells and then lymphocyte antigens (HLA antigens) w ere tested using standard microlymphocytotoxicity typing methods o n pre- and post-treated lymphocyte suspension. The results ar e shown in Table VIII. TABLE VIII HLA antigen HLA ar tibody Reading Score*** Reading Score*** speci ficitv numb fir in tray Untreated PEG Treated** 10 D* All IF 8 8 8 All 2F 8 1 1 All 2E 6 6 8 All 2D 4 1 All 2C 4 1 All 5D 4 1 A24 4B 8 6 6 A24 5A 8 1 A24 5B 8 8 B62 IE 8 2 B62 IF 8 1 B62 2F 4 1 B62 2E 6 1 B62 2A 8 1 B62 7D 8 4 8 B62 7E 8 1 BW4 10E 6 1 BW6 10D 8 4 BW6 IOC 8 2 BW6 10B 8 1 BW6 10A 8 8 8 * Lymphocytes treated with PEG-albumin copolymer and incubated in RPMIfor 10 d. ** Lymphocytes (HLA typing: All, A24, B 62, BW4 & BW6) treated with PEG-albumin copolymer. ***Score 1 and 2 = negative reaction; 4=weak reaction; 6=moderate reaction; 8=strong reaction The results contained in Tables VI, VII and VIII show that the PEG-albumin copolymer conjugated to lymphocyte surfaces could block or decrease exposure of antigens to most HLA antibodies. This blocking effect can continue at least 10 days . These results support that this method can not only block red cell surface antigens, but also block other cell's surface antigens from reacting to various antibodies. References Fratantoni, J. ( 1 991 ) Points to consider in the s afety evaluation of hemoglobin-based oxygen carriers. Transfusion 3~:369-37~. Griffiths, B., Cortes, A., Gilbert, N., Stevenson, P., MacDonald, S., Pepper, D. ( 1995) Haemoglobin-based blood substitutes a n d sepsis. Lancet 345 : 158- 160. Harris, J.M. 1992) Introduction to Biotechnical a n d Biomedical applications of poly(ethylene glycol), pp.1 -14 i n Poly(Ethylene Glycol) Chemistry, Ed.: 3.M. Harris, Plenum Publishing, New York, NY Issitt P.D. (1985) App fled Blood Group Serology, Montgomery Scientific Publications, Miami, FL LoBuglio, A.F., Court, W.S., Vinocur, L., Maglon, 0., Shaw, GM. (1983) Immune thrombocytopenic purpura. Use of I * 25 -labeled antihuman IgG monoclonal antibody to quantify platelet-bound IgG. New Engl. J. Med. 309:459-463. Mollison, P.L., Engelfriet C.P., Contreras M. (1987) Blood Transjitsion in Clinical Medicine (Blackwell Scientific Publications, Oxford, ed. 8, 1987), pp.195-636. Walker, R.H. (1990) Technical Manual, 10th Edition, American Association of Blood Banks, Arlington, VA. Zalipsky, S. and Lee, C. (1992) Use of functionalized poly(ethylene glycol)s for modification of polypeptides, pp .347 - 370, in Poly(ethylene Glycol) Chemistry, Ed.: J.M. Harris, Plenum Publishing, New York, NY. Read, E.J., Cardine, L.L., Yu, M.Y. (1991) Flow cytometric detection of human red cells labeled with a fluorescent m embrane label: potential application to in vivo survival studies. Transfusion 31 (6) : 5 * 02-508 Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the a r t to which the invention pertains. These patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. One skilled in the art will readily appreciate that th e present invention is well adapted to carry out the objects a n d obtain the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods , procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within th e spirit of the invention as defined by the scope of the claims.

Claims: WHAT IS CLAIMED IS: 1 . A composition of matter, comprising a red blood cell coated with a cross-linked or branched polyethylene glycol and albumin. 2. The composition of claim 1, wherein said branched polyethylene glycol is an arm polyethylene glycol. 3. The composition of claim 2, wherein said arm polyethylene glycol is a 4 arm polyethylene glycol. 4. The composition of claim 3, wherein said a rm polyethylene glycol is 4 arm propionyl-N-hydroxysuccinimide- methoxypolyethylene glycol. 5. The composition of claim 1 , wherein th e concentration of said polyethylene glycol is from about 0.5% to about 1 %. 6. The composition of claim 1 , wherein th e concentration of said albumin is from about 1.25% to about 10%. 7. The composition of claim 1, wherein said albumin is human albumin. 8 The composition of claim 1 , wherein the cell i s coated with polymeric mixture at least one time. 9. A method of blocking blood group antigens on the surface of a red blood cell, comprising the step of contacting said cell with a pharmacologically effective concentration of th e composition of claim 1. 1 0. The method of claim 9, wherein th e concentration of said polyethylene glycol is from about 0.5% to about 1 %. 1 1 . The method of claim 9, wherein th e concentration of said albumin is from about 1.25% to about 10%. 1 2. The method of claim 9, wherein said albumin is human albumin. 1 3. A composition of matter, comprising a red blood cell coated with a cross-linked or branched polyethylene glycol and branched polyethylene glycol amine. 14. A composition of matter, comprising a red blood cell coated with a cross-linked or branched polyethylene glycol and an albumin-like compound, wherein said compound contains multiple reaction sites which form a cross-linked matrix with activated esters of polyethylene glycol. 1 5. A composition of matter, comprising a cell coated with a cross-linked or branched polyethylene glycol and a protein. 1 6. The composition of claim 15, wherein said cell is a red blood cell. 1 7. The composition of claim 15, wherein s aid protein is albumin. 1 8. The composition of claim 15, wherein said polyethylene glycol is a branched polyethylene glycol. 1 9. The composition of claim 15, wherein said protein contains multiple reaction sites which form a cross-linked matrix with of polyethylene glycol.

Inventors: HORTIN GLEN L, HUANG SHU T, HORTIN, GLEN, L., HUANG, SHU, T.
Applicants: UAB RESEARCH FOUNDATION
Application year: 1998
Main classification: A01N63
IPC codes: A01N1, A61K35